title: Brentuximab vedotin in combination with or without donor lymphocyte infusion for patients with Hodgkin lymphoma after allogeneic stem cell transplantation.
abstract: In our study, we evaluated the safety and efficacy of Brentuximab vedotin (BV) with or without the addition of donor lymphocyte infusion (DLI) after allogeneic stem cell transplantation (allo-SCT) in 16 patients with advanced Hodgkin lymphoma (HL). Thirteen patients with relapsed HL after allo-SCT received BV as treatment for active disease. Three patients without progression of HL after allo-SCT received BV as consolidation. Twelve patients had been previously exposed to BV for treatment of relapse after autologous-SCT. Ten out of 16 patients received BV in combination with DLI. Among the 13 patients treated for active disease, CR and PR was observed in 7 and 2 patients, respectively. With a median follow-up of 13 months, 13 out of 16 patients are alive, while 3 died because of disease progression. The median PFS was 6 months. DLI-associated GVHD occurred in seven patients. Five patients with GVHD required immunosuppression, and in all cases, GVHD resolved after a short course of low dose steroids, implying that an anti-GVHD modulating effect could be induced by the concurrent administration of BV. No serious adverse event was observed in any of the patients.
authors.affiliation: Second Department of Internal Medicine, ATTIKO University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: P
authors.initials: P
authors.lastname: Tsirigotis
authors.affiliation: Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel.
authors.forename: I
authors.initials: I
authors.lastname: Danylesko
authors.affiliation: Second Department of Internal Medicine, ATTIKO University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: K
authors.initials: K
authors.lastname: Gkirkas
authors.affiliation: Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel.
authors.forename: N
authors.initials: N
authors.lastname: Shem-Tov
authors.affiliation: Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel.
authors.forename: R
authors.initials: R
authors.lastname: Yerushalmi
authors.affiliation: Second Department of Internal Medicine, ATTIKO University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Stamouli
authors.affiliation: Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Avigdor
authors.affiliation: Bone Marrow Transplantation Unit, University of Patras, Patras, Greece.
authors.forename: A
authors.initials: A
authors.lastname: Spyridonidis
authors.affiliation: Bone Marrow Transplantation Unit, University of Lille, Lille, France.
authors.forename: J
authors.initials: J
authors.lastname: Gauthier
authors.affiliation: Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Goldstein
authors.affiliation: Bone Marrow Transplantation and Hematology & Lymphoma Department, Evaggelismos General Hospital, Athens, Greece.
authors.forename: J
authors.initials: J
authors.lastname: Apostolidis
authors.affiliation: Department of Hematology, Hospital St Antoine, Paris, France.
authors.forename: M
authors.initials: M
authors.lastname: Mohty
authors.affiliation: Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Shimoni
authors.affiliation: Hematology Division, Chaim Sheba Medical Center, Tel Aviv, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Nagler
mesh_terms: D000293:Adolescent; D000328:Adult; D000079963:Brentuximab Vedotin; D003131:Combined Modality Therapy; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy / Q000209:etiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods*; D006689:Hodgkin Disease / Q000150:complications / Q000401:mortality / Q000628:therapy*; D006801:Humans; D018796:Immunoconjugates / Q000008:administration & dosage* / Q000009:adverse effects; D017710:Lymphocyte Transfusion; D008297:Male; D013256:Steroids / Q000627:therapeutic use; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D013256:Steroids; D000079963:Brentuximab Vedotin